Multicenter retrospective study of usefulness of the pretreatment inflammatory biomarker for the uterine sarcoma

Multicenter retrospective study of usefulness of the pretreatment inflammatory biomarker for the uterine sarcoma - Multicenter retrospective study of usefulness of the pretreatment inflammatory biomarker for the uterine sarcoma

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000045580

Enrollment

150

Registered

2021-10-01

Start date

2021-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Uterine sarcoma, Uterine carcinosarcoma

Interventions

None listed

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Patients who received surgery from January 2008 to December 2017, and be diagnosed malignant mesenchymal tumors. Malignant mesenchymal tumors include the following: mooth muscle tumor of uncertain malignant potential (STUMP) Leiomyosarcoma Low-grade endometrial stromal sarcoma High-grade endometrial stromal sarcoma Undifferentiated uterine sarcoma Uterine tumor resembling ovarian sex cord tumor(UTROSCT) Rhabdomyosarcoma Perivascular epithelioid cell tumor(PEComa) Adenosarcoma Carcinosarcoma

Exclusion criteria

Exclusion criteria: Patients who are complicated with blood malignancy such as leukemia.

Design outcomes

Primary

Measure	Time frame
Progression free survival	—

Secondary

Measure	Time frame
Overall survival	—

Countries

Japan

Contacts

Public ContactKen Yamaguchi

Kyoto University Graduate School of Medicine Department of Gynecology and Obstetrics

mandai@kuhp.kyoto-u.ac.jp0757513269

Outcome results